Clinical Trial Update: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at City of Hope is evaluating a three-drug combination of acalabrutinib, obinutuzumab, and glofitamab for relapsed or refractory mantle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Columvi (glofitamab)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING